Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Erasca, Inc. ERAS NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
48/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$11.60
-35%

Erasca, Inc. (ERAS) is a Biotechnology company in the Healthcare sector, currently trading at $17.85. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is ERAS = $12 (-35% upside).

Valuation: ERAS trades at a trailing Price-to-Earnings (P/E) of -39.1 (S&P 500 average ~25).

Net income is $125M (loss), growing at +13.7%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $47M against $325M equity (Debt-to-Equity (D/E) ratio 0.14, conservative). Current ratio is 10.04 (strong liquidity). Debt-to-assets is 11.9%. Total assets: $396M.

Analyst outlook: 8 / 10 analysts rate ERAS as buy (80%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 80/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 58/100 (Partial), Income ?/100 (Fail).

$11.60
▼ 35.01% Downside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for Erasca, Inc., the average price target is $11.60, with a high forecast of $20.00, and a low forecast of $5.00.
Highest Price Target
$20.00
Average Price Target
$11.60
Lowest Price Target
$5.00

ERAS SharesGrow Score Overview

58/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 10/100
Valuation — P/E, PEG, Forward PEG
GROWTH 80/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 58/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ERAS

✗
VALUE Fail
10/100
ERAS trades at a trailing Price-to-Earnings (P/E) of -39.1 (S&P 500 average ~25). Forward PEG -1.92 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $12, implying -32.8% from the current price $18. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
80/100
ERAS: +0%/yr revenue is, +13.7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ERAS: Debt-to-Equity (D/E) ratio 0.14 (conservative), Current ratio is 10.04 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
ERAS: Gross margin is 0% (+0 pp trend), $6B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
58/100
Analyst outlook: 8 / 10 analysts rate ERAS as buy (80%). Analyst consensus target is $12 (-32.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.01-18.18
Volume5.27M
Avg Volume (30D)5.68M
Market Cap$5.55B
Beta (1Y)1.05
Share Statistics
EPS (TTM)-0.44
Shares Outstanding$283.53M
IPO Date2021-07-16
Employees103
CEOJonathan E. Lim
Financial Highlights & Ratios
Gross Profit$-3.11M
EBITDA$-128.3M
Net Income$-124.55M
Operating Income$-131.41M
Total Cash$276.08M
Total Debt$47.14M
Net Debt$-26.67M
Total Assets$396.15M
Price / Earnings (P/E)-40.6
Analyst Forecast
1Y Price Target$11.00
Target High$20.00
Target Low$5.00
Upside-38.4%
Rating ConsensusBuy
Analysts Covering10
Buy 80% Hold 10% Sell 10%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS29479A1088

Price Chart

Track all markets on TradingView
ERAS
Erasca, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
1.01 52WK RANGE 18.18

People Also View

EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 RLAY
RLAY
Relay Therapeutics, Inc.
$14.75
-3.34%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 OLMA
OLMA
Olema Pharmaceuticals, Inc.
$16.30
+2.32%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 SANA
SANA
Sana Biotechnology, Inc.
$3.48
+8.41%
 LIFE
LIFE
aTyr Pharma, Inc.
$14.69
+2.23%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message